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A B S T R A C T
Pharmacopoeial methods for measurement of the aerodynamic particle size distribution (APSD) of
metered dose inhalers (MDIs) by cascade impaction specify a sampling ﬂow rate of 28.3 L/min. However,
there is little data within the literature to rationalize this ﬁgure, or to support its clinical relevance. In
addition, the standard United States Pharmacopoeia Induction Port (USP IP) used for testing is known to
inaccurately reﬂect deposition behavior in the upper airway, further compromising the relevance of
testing, for product development.
This article describes experimental studies of the effect of sampling ﬂow rate on APSD data gathered
using an Andersen Cascade Impactor (ACI). Tests were carried out using two different formulations to
assess the inﬂuence of formulation composition. In addition, comparative testing with an Alberta
Idealised Throat, in place of the USP IP, to ensure more realistic representation of the upper airway.
The results show how measured APSD and ﬁne particle dose, the dose than on the basis of size would be
expected to deposit in the lung, vary as a function of test methodology, providing insight as to how the
testing can be modiﬁed towards greater clinical relevance.
ã 2016 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Pharmacopoeial methods for measuring the aerodynamic
particle size distribution (APSD) of metered dose inhalers (MDIs)
specify the application of a 28.3 L/min sampling ﬂow rate during
testing. However, there is little data within the literature to
rationalise this test condition and it may be that it was originally
speciﬁed on the basis of the measurement capabilities of the
Andersen Cascade Impactor (ACI), rather than direct clinical
signiﬁcance (Byron et al., 2004). As MDIs are propellant-driven it
has been argued that the size of particles produced should not be
affected by test conditions. Furthermore Chapter <601> of the
United States Pharmacopoeia (USP) arguably gives the impression
that using the ACI at ﬂow rates other than 28.3 L/min is
unacceptable, and a standard test ﬂow rate has remained in place
for many years (Schumacher and Leiner, 2012). The standard USP/
Ph.Eur. induction port (IP) is also deployed routinely for APSD
measurement although there is widespread recognition that this* Corresponding author at: Chippenham Research Centre, Chiesi Limited, Units
T1-T3, Bath Road Industrial Estate, Chippenham, Wiltshire SN14 0AB, UK.
E-mail address: d.lewis@chiesi.com (D.A. Lewis).
http://dx.doi.org/10.1016/j.ijpharm.2016.05.025
0378-5173/ã 2016 The Author(s). Published by Elsevier B.V. This is an open access artifails to accurately reﬂect deposition behaviour in the upper airway
of adults (Zhou et al., 2011).
In this article, we present new data from three experimental
set-ups that suggest that the assumption that APSD measurements
for MDIs are unaffected by sampling ﬂow rate may be ﬂawed. The
results highlight the potential to make testing more relevant to
clinical practice and outcomes, by modifying test ﬂow rate and IP
choice, where the aim is maximise understanding of the product to
support effective development.
2. Drug delivery with MDIs
Inhalation therapy is the mainstream treatment for bronchial
asthma, chronic obstructive pulmonary disease (COPD), and other
lung diseases, and hand-held devices including MDIs are most
regularly used as treatment. These are formulated either as
solutions or suspensions. Suspension MDIs consist of a drug in a
solid phase, which is dispersed along with other formulation
constituents in a suitable propellant vehicle. Solution MDIs on the
other hand consist of the active ingredient dissolved in a pure or a
mixture of propellants (Newman, 2005).
MDIs owe their popularity to their low cost, clinical effective-
ness, simplicity, portability and suitability for virtually all drugscle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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principle of operation of MDIs currently available on the market
remains similar to the original 1950s push-and-breath design,
whereby upon actuation of the MDI, the metering chamber, which
holds a deﬁned volumetric dose, becomes closed to the formula-
tion reservoir and open to the atmosphere. This results in
expansion of the propellant-based formulation and atomisation
through the actuator oriﬁce6. Depending on the product, 9–50% of
the drug mass metered by a correctly used MDI is able to reach a
patient’s lungs. The rest is either deposited in the valve stem,
actuator and valved holding chamber (VHC) (if present) or within
the patient’s oropharyngeal region (Rau, 2005, 2006).
The aerodynamic size of particles delivered by an MDI
correlates with regional deposition in the lungs and respiratory
tract, and consequently has a direct inﬂuence on the success of
drug delivery. Effective delivery of the active pharmaceutical
ingredient(s) (API) relies upon achieving dispersion to a particle
size of <5 mm, as large particles (5–10 mm) tend to be deposited in
the upper airways (Nave and Mueller, 2013). Cascade impaction
enables the differentiation of API’s from other components within
the formulation to provide an APSD for the API alone and is
consequently a key analytical method for the development and
quality assurance of MDIs and other inhaled products (Copley,
2008).Fig. 1. Photographs of ACI conﬁgurations 1–5. Conﬁgurations 1–3 utilise a single ACI 
extension (24.5 mm internal diameter) between the USP/Ph.Eur. IP and the ACI. Conﬁgu
Conﬁgurations 4 and 5 use two ACIs and three ACIs coupled together. Connectors were3. In vitro MDI testing—measuring APSD
Cascade impactors are relatively simple devices, which separate
a sample on the basis of differences in particle inertia. They consist
of a series of stages, each with a speciﬁc nozzle arrangement and
associated collection surface. A vacuum pump draws a constant
ﬂow of sample-laden air sequentially through each stage (Copley,
2008). At each stage particles with sufﬁcient inertia will cross the
air streamlines and impact on the impaction surface while those
with less will follow the airﬂow away from the impaction area. Any
residual materials are captured in a ﬁnal collector, usually a ﬁlter.
The mass of the collected particles can subsequently be deter-
mined on a stage-by-stage basis using an appropriate recovery/
assay method(s) for the APIs present.
The original ACI, designed in 1956, utilised a ﬂow rate of 1 cfm
(equivalent to 28.3 L/min), to produce a stage cut off of 1 mm for the
last stage. The more familiar MkII ACI used today was developed in
1977, and since then the only alteration regarding MDI sampling,
has been deﬁnition of the IP dimensions, although ACI modiﬁed
stacks have been developed for the use of alternative ﬂow rates in
dry powder inhaler (DPI) testing (Mitchell and Roberts, 2013;
Nichols and Smurthwaite, 1998).
The non viable ACI containing ﬂat, circular collection plates
rather than Petro dishes utilized with the ‘viable’ form of this
impactor ACI ﬁtted with a USP/Ph.Eur. IP was ﬁrst proposed during
the 1990’s as a pharmacopoeia methodology for measuring the
APSD of suspension and solution MDIs. This methodology has sinceand IP, as described in the USP/Ph.Eur. Conﬁguration 2 includes a 600 mm length
ration 3 incorporates a VHC (Aerochamber PlusTM, Trudell Medical) prior to the IP.
 manufactured to join the stacks to a single IP.
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and European pharmacopoeia (USP and Ph. Eur.) monographs for
inhaled products (Ph.Eur. Chapter 2.9.44; USP <601>). It speciﬁes
that sampling is conducted at 28.3 L/min, to mimic slow
inspiration through the device (Newman, 2009).
One of the earliest references to measuring under alternative
ﬂow rates was from Couchman (1965) who used a ﬂow rate of 18 L/
min to more accurately simulate human breathing proﬁles
(Couchman, 1965). Since then other experimental studies have
suggested that MDI drug delivery characteristics may be depen-
dent upon sampling ﬂow rate (Shemirani et al., 2013).
The suitability of the IP used in APSD testing has also come
under scrutiny. Despite proving satisfactory as a standardised piece
of equipment for QC, the ﬂow characteristics and deposition
behaviour within the USP/Ph.Eur. IP design is recognized as
providing only as rudimentary representation of the upper airway
(Zhou et al., 2011). The use of alternative interfaces to improve
correlations between in vitro and in vivo data to more accurately
assess the performance of MDIs within a clinical setting, therefore
continues to prompt research (Copley, 2013). One development
has been the adult ‘Alberta’ Idealised Throat (A-AIT); a more
realistic IP, that has been shown to more accurately mimic aerosol
behaviour in the patient throat.
In the experimental studies reported here we assessed the
impact of impactor conﬁguration, including sampling ﬂow rate and
choice of IP on the APSDs measured from different MDI-based
formulations to support the development of protocols that more
relevantly support R&D. The conﬁgurations presented here allow
impact assessment of sample ﬂow rate on in vitro measurements of
MDI performance whilst maintaining ACI stage cut-offs. Breath
simulators have not been included in this study and are outside the
scope of this work.
4. Experimental study 1: assessing the impact of sampling ﬂow
rate
4.1. Materials and methods
Five experimental ACI conﬁgurations were used (Fig. 1) to
assess the impact of sampling ﬂow rates and test set-up.
Conﬁgurations 1, 2 and 3 all utilised a single ACI and USP/Ph.
Eur. IP, but Conﬁguration 2 included a 600 mm length extensionFig. 2. (a) Cumulative mass undersize and (b) cumulative percentage und(25.4 mm internal diameter) between the USP/Ph.Eur. IP and ACI, to
ensure a signiﬁcant increase in IP volume and path length prior to
the ACI. Conﬁguration 3 incorporated a VHC (Aerochamber PlusTM,
Trudell Medical, Nottingham, UK) prior to the IP. Conﬁgurations 4
and 5 used two ACIs and three ACIs coupled together, respectively,
to enable measurement at higher MDI Mouthpiece ﬂow rates,
whilst maintaining a constant ﬂow rate of 28.3 L/min through each
impactor. Connectors were manufactured to join the stacks to a
single IP, with all extra hardware manufactured (Chiesi Limited,
Chippenham, UK) from Vero Clear RGD 810 or Vero Clear RGD840
using a Project 30 3D printer. Internal tube diameters were
matched to that of the USP/Ph.Eur. IP’s exit (25.4 mm) and the
additional internal path length was chosen to be 150 mm to allow
for adjacent impactor placement. The mass of API deposited upon
the connectors and IP extension was established to be less than
0.2% of each MDI actuation.
Conﬁgurations 1, 2 and 3 were tested with a sampling rate of
28.3 L/min, while Conﬁgurations 4 and 5, enabled sampling ﬂow
rates at the mouthpiece of 56.6 L/min and 84.9 L/min, respectively
to be attained. Mouthpiece ﬂow rates were veriﬁed with a
calibrated mass ﬂow meter and the volumetric ﬂow rate through
each ACI stack veriﬁed using in-line calibrated volumetric ﬂow
meters. Each conﬁguration was conﬁrmed to be leak tight and have
acceptable critical dimensions; using the methodologies described
in Good Cascade Impactor Practice (Nichols et al., 2013).
All conﬁgurations were evaluated using Fostair MDIs (Chiesi
Farmaceutici, Parma): ethanol based solution, HFA 134a formu-
lations, containing 100 mg Beclomethasone Dipropionate (BDP)
and 6 mg Formoterol Fumarate (FF). Three MDIs were evaluated for
each conﬁguration, with all actuations delivered in accordance
with the Patient Instruction Leaﬂet (PIL). ACI stages were coated
prior to actuationdelivery using a placebo MDI (O’shea and Lewis,
2011). Drug recovery was performed by quantitative extraction
from the actuator, USP/Ph.Eur. IP and ACI stages; and mass of BDP
within test samples was determined by Ultra Performance Liquid
Chromatography (UPLC) with Single Quad Detector (SQD, Waters,
Elstree, UK). The FF component of the formation was not analysed
as it has been proven to produce the same characteristics as BDP
(Lewis et al., 2006).
Drug mass deposition was determined separately for each ACI
stage. Two actuations were required for robust detection for
Conﬁgurations 1, 2 and 3, four actuations for Conﬁguration 4, andersize, for ACI conﬁgurations 1, 2 & 3 (Q = 28.3 L/min, n = 3, St.Dev.).
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mean and standard deviation for each experimental condition.
Data processing was performed utilising CITDAS V3.10 (Copley,
Nottingham, UK) and all data are presented, normalized to a single
actuation of the inhaler.
4.2. Results
Within each conﬁguration, average MDI actuator deposition
was 9.5 1 mg; approximately 10% of the observed average BDP
metered dose, 97  3 mg. Comparing the data for Conﬁgurations 1–
3 indicates that it is the inclusion of a VHC prior to the IP that had
the greatest impact on dose characteristics. IP deposition was
reduced from 49  2 mg and 51  2 mg for Conﬁgurations 1 and 2,
respectively, to just 3  0.2 mg, with Conﬁguration 3, with a
concomitant 20 mg increase in ﬁne particle dose (FPD); despite
some API deposition to the interior surfaces of the VHC. Fig. 2a
illustrates the effect on the cumulative mass of BDP less than 5 mm
diameter, with a similar, but lesser effect also observed when
comparing data from Conﬁguration 1 and 2. For Conﬁguration 2
and 3 the mass of BDP deposited on ACI stage 0 and stage 1 was
signiﬁcantly reduced (p < 0.05).
Drug deposition data for Conﬁgurations 4 and 5 showed a
signiﬁcant decrease (p < 0.001) in USP/Ph.Eur. IP deposition as the
MDI mouthpiece sampling ﬂow rate (Q) was increased from 28.3 L/
min to 56.6 L/min and 86.9 L/min, respectively, which resulted in
an increased mass of drug reaching the ACI. Furthermore, a
signiﬁcant (p < 0.001) increase was observed in the FPD; from
33  2 mg to 55  3 mg, when Q was increased from 28.3 L/min to
56.6 L/min, though no signiﬁcant further rise in FPD was observed
when Q was further increased to 86.9 L/min (FPD = 56  3 mg).
The effect of mouthpiece sampling ﬂow rate on Mass Median
Aerodynamic Diameter (MMAD) was marginal (see Fig. 3b): a
reduction from 1.4 mm at 28.3 L/min (Conﬁguration 1) to 1.2 mm at
56.6 L/min and 1.1 mm at 86.9 L/min. This was due to approxi-
mately 11 1% of drug mass being associated with particles greater
than 4.7 mm aerodynamic diameter at a mouthpiece ﬂow rate
Q = 28.3 L/min, compared to just 2  1% of drug mass when
Q = 56.6 L/min and 86.9 L/min. When sampling with ConﬁgurationsFig. 3. (a) Cumulative mass undersize and (b) cumulative percentage undersize, for ACI 
mass <5 mm increases and APSD narrows when sampling ﬂow rate is increased above4 and 5, a narrower APSD, shifted to ﬁner sizes was obtained
compared to Conﬁguration 1 (Geometric SD: 2.24  0.07 (Conﬁgu-
ration 1), 1.71 0.02 (Conﬁguration 4) and 1.69  0.03 (Conﬁgura-
tion 5)). A rationalisation for this behaviour was that the higher
sampling ﬂow rates dilute the concentration of the propellant and
ethanol vapour around the plume, such that propellant ﬂashing
and ethanol evaporation rates were increased (Stein and Myrdal,
2006). The effect almost eliminates >5 mm aerodynamic diameter
droplets detected in the impactor with Conﬁgurations 4 and 5
(Fig. 3b).
4.3. Discussion
It has been previously reported that with ethanol solution MDIs
such as the one tested here, ethanol itself is deposited on stages 0
and 1 under standard sampling conditions (Stein, 2008; Mitchell
et al., 2009); highlighting that evaporation mechanisms may be
incomplete prior to droplet deposition within the ACI. The added
time for ethanol evaporation provided by Conﬁgurations 2 and 3
may be responsible for the reduction in the mass deposited on the
upper stages, compared with Conﬁguration 1. However, this had
little effect on FPD, as IP deposition remained comparable between
Conﬁgurations 1 and 2. As the sampling ﬂow rate at the
mouthpiece remained identical (28.3 L/min), the mass of deposi-
tion caused by turbulent dispersion at the IP entrance was
unchanged (Versteeg and Hargrave, 2006). In contrast the location
of the spacer resulted in a reduction in the speed of the plume
before it entered the IP, reducing the ballistic component of the
aerosol plume and the amount of deposition.
For an MDI with a ﬁxed mass discharge rate, increasing
mouthpiece sampling ﬂow rate provides a greater volume of air
relative to the volume of formulation (a factor of two when
Q = 56.6 L/min, or three when Q = 86.9 L/min) after propellant
ﬂashing has taken place. Hence, enhanced ethanol evaporation can
be anticipated, at these patient relevant mouthpiece ﬂow rates
leading to reduced particle deposition on the ACI stages with
associated aerodynamic diameters >5 mm, as observed.
It is pertinent to note that utilising a Next Generation Impactor
(NGI), De Maria et al. (2014) reported the MMAD of Foster MDIs toconﬁgurations 1, 4 & 5 (Q = 28.3, 56.6, 84.9 L/min) show that the magnitude of drug
 28.3 L/min.
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1.0  0.1 mm respectively). However, the work presented here,
showed FPD was dependent upon testing ﬂow rate: 34  2 mg at
30 L/min and 47  2 mg at 60 L/min, respectively; i.e. similar to the
values presented in Table 1 at the lower ﬂow rate (33  2 mg,
Conﬁguration 1) but a reduced FPD at 60 L/min compared with
Conﬁguration 4 (55  3 mg at 56.6 L/min). These data therefore
highlight how the in-vitro performance data of solution MDIs is
sensitive to the exact conﬁguration of the impactor; a ﬁnding
echoed by a study involving an evaluation of the Fast Screening
Impactor (FSA) (Keegan and Lewis, 2012a,b).
The Fostair product is licensed for use with the Aerochamber
Plus VHC (Conﬁguration 3) to reduce IP deposition, and potentially
patient oro-pharyngeal drug deposition. The increased time
available for reduction in plume speed and ethanol evaporation
also increased FPD compared with Conﬁguration 1. The advantages
of using VHCs are well documented (Nikander et al., 2014; Shim,
2000; Brennan et al., 2005). The results presented here show fast
inhalation through a low resistance MDI potentially improves the
drug delivery obtained with solution-based MDIs, and may result
in similar performance to that observed with a spacer.
5. Experimental study 2: assessing the impact of formulation
properties
5.1. Materials and methods
In an extension to the initial study, the effect of patient-relevant
sampling ﬂow rates on the performance of alternative formula-
tions was investigated. Two ethanol-containing, solution formu-
lations were designed. Formulation A contained HFA 227, and
formulation B contained HFA 134a and glycerol. The three
experimental ACI conﬁgurations utilised were Conﬁgurations 1,
3 and 5 (Fig. 1). The VHC used in Conﬁguration 3 was primed using
two actuations of the test formulation prior to evaluation. Testing
practice, drug recovery and data processing were all performed as
per the previous case study.
5.2. Results
Delivery of the two formulations using the industry-standard
Conﬁguration 1 conﬁrmed that the key aerosol performance
parameters were equivalent, with FPDs of 68  2 mg and 71 3 mg;Table 1
BDP deposition within ACI conﬁgurations 1–5 and summary aerosol characteristics (Av
Conﬁguration 1 2 
Q, Flow Rate at MDI Mouthpiece [L/min] 28.3 28.3
Actuator [mg] 10.4  0.3 10.0
VHC [mg] N/A N/A
USP/Ph.Eur. IP [mg] 49.1  1.9 50.9
Connector [mg] N/A 0.3 
Stage 0 [mg] 3.0  0.3 0.6 
Stage 1 [mg] 0.8  0.1 0.3 
Stage 2 [mg] 0.4  0.1 0.5 
Stage 3 [mg] 1.3  0.2 2.5 
Stage 4 [mg] 5.5  0.3 7.3 
Stage 5 [mg] 12.7  1.1 11.4
Stage 6 [mg] 6.6  0.5 6.0 
Stage 7 [mg] 3.1  0.2 2.6 
Filters [mg] 4.0  0.2 6.2 
Metered Dose [mg] 97  1 98 
Delivered Dose [mg] 87  1 88 
Fine Particle Dose [mg] 33  2 36 
Fine Particle Fraction [%] 39  2 41 
MMAD [mm] 1.4  <0.1 1.4 
GSD 2.2  0.1 2.1 and MMADs of 2.4 mm and 2.5 mm (see Table 2). In fact, the APSD
data of both formulations remained comparable for all impactor
conﬁgurations (Figs. 4 and 5).
Addition of a spacer (Conﬁguration 3) resulted in an increased
ﬁne particle fraction (%FPF) with both formulations (Table 2), as
observed in the initial study. IP deposition was reduced but the
delivered FPD of Formulation A remained very similar whereas
that of Formulation B increased from 71 3 mg to 100  13 mg. A
greater mass of BDP was deposited on the VHC from Formulation A
than Formulation B (156  18 mg compared with 125 12 mg).
Increasing the sampling ﬂow rate to 84.9 L/min (Conﬁguration
5) further increased the FPDs of both formulations (Table 2). This
effect corresponded with a decrease in IP deposition, compared
with Conﬁguration 1 and was particularly marked for Formulation
B.
5.3. Discussion
In the studies, the effect of impactor conﬁguration was observed
to be dependent on the components of the formulation, in
particular the propellant. HFA 134a had a higher vapour pressure
than HFA 227 (570 and 390 kPa at 20 C respectively), thus the pack
pressure of Formulation B was greater than Formulation A, despite
the addition of non-volatile excipients to the HFA 134a formula-
tion. A higher pack pressure has been reported to produce ﬁner
sprays (Brambilla et al., 1999); at the sampling ﬂow rate of 28.3 L/
min used in Conﬁguration 1 but under standard sampling
conditions the effect of oriﬁce diameter appeared to be sufﬁcient
to overcome this effect, and similar FPDs were observed for both
formulations. However this was not the case when using
Conﬁgurations 3 and 5.
The initial ﬂashing of a formulation causes rapid cooling at the
oriﬁce exit. This can inhibit atomisation of the propellant if the
temperature falls below its boiling point, potentially causing a
reduction in FPD (Usmani et al., 2003). This process, if it occurs, is
more likely to affect formulations containing HFA 227, which has a
higher boiling point than HFA 134a (16.5 C and 23.6 C
respectively). An increase in the air ﬂow rate past the oriﬁce
may enhance movement away from the oriﬁce exit into a warmer
environment, preventing this inhibition. This effect would
rationalise the higher FPDs observed with Conﬁguration 5 relative
to Conﬁguration 1.erage  Standard Deviation).
3 4 5
 28.3 56.6 84.9
  1.1 7.4  0.3 9.5  1.1 10.1  0.3
 26.2  0.9 N/A N/A
  2.0 3.3  0.2 35.0  1.4 28.6  1.8
N/A 0.17 0.2
 0.1 0.2  0.1 0.5  0.1 0.3  0.1
 0.1 0.1  0.0 0.3  0.1 0.3  0.1
 0.1 0.2  0.1 0.2  0.1 0.3  0.1
 0.4 1.2  0.2 0.9  0.2 0.8  0.0
 0.6 9.6  0.4 5.8  0.4 5.0  0.1
  0.4 24.6  1.2 22.5  0.7 22.6  1.7
 0.1 12.6  0.6 13.4  1.4 15.2  1.0
 0.2 5.1  0.6 5.9  0.5 6.3  0.4
 0.5 2.8  0.7 6.0  1.0 5.5  0.3
 3 93  0.4 100  1 95  2
 3 60  1 91  1 85  2
 1 56  1 55  3 56  3
 1 94  0.4 60  2 65  3
 0.1 1.3  0.1 1.2  <0.1 1.1  <0.1
 <0.1 1.8  <0.1 1.7  <0.1 1.7  <0.1
Table 2
Summary aerosol characteristics for formulations A & B, ACI conﬁgurations 1, 3 and 5.
(Mean  Standard Deviation)
Conﬁguration 1 1 3 3 5 5
Formulation A B A B A B
Q, Flow Rate at MDI Mouthpiece [L/min] 28.3 28.3 28.3 28.3 84.9 84.9
Metered Dose [mg] 257  3 249  4 272  8 261  4 261  5 259  2
Delivered Dose [mg] 229  3 223  3 86  9 111  15 230  4 232  3
Fine Particle Dose [mg] 68  2 71  3 74  8 100  13 100  1 137  8
Fine Particle Fraction [%] 30  1 32  2 86  3 90  1 44  0.1 59  4
MMAD [mm] 2.4  <0.1 2.5  <0.1 2.1  0.1 2.2  < 0.1 1.9  0.1 2.0  0.1
GSD 2.9  0.3 2.2  0.1 2.7  0.1 2.0  <0.1 2.1  0.1 1.8  <0.1
Fig. 4. Cumulative percentage undersize for formulations A & B, ACI conﬁgurations 1, 3 and 5 (left to right).
Fig. 5. Cumulative mass undersize for formulations A & B, ACI conﬁgurations 1, 3 and 5 (left to right).
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adult alberta idealised throat
In a ﬁnal set of experiments, results obtained using the A-AIT
(Fig. 6) were compared with those from the USP/Ph.Eur. IP, set-up
as per Conﬁgurations 1 and 5 in the ﬁrst experiment. Experimental
conditions, drug recovery and data processing were as per the
preceding studies.6.1. Materials and methods
Three commercial products were selected to assess the effect of
the IP with different formulation: Foster (Chiesi Farmaceutici,
Italy); an ethanol-containing (12% w/w), HFA 134a solution
formulation; Flutiform (Mundipharma, UK); and Flixotide (Glax-
oSmithKline, UK); suspension formulations in HFA 227 and HFA
134a respectively. Flutiform also contains a small amount of
ethanol (1 mg per puff, approximately 1.3% w/w).
Fig. 6. Adult Alberta Idealized Throat (AIT); cross sectional internal USP/Ph.Eur. IP geometry superimposed.
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The results obtained indicate that at a sampling rate of 28.3 L/
min, FPD (<5 mm aerodynamic diameter) was independent
(p > 0.05) of IP choice (see Fig. 7). However, at 84.9 L/min, the
FPD of all three products was found to depend on the selected IP
(p < 0.05). Thus, the A-AIT gave a consistent (p > 0.05) FPD for
Foster (31 1 mg & 35  3 mg) and Flixotide (46  5 mg & 41 1 mg)
at both ﬂow rates. However, a signiﬁcant (p < 0.05) drop in FPD
50  1 mg (28.3 L/min) to 38  3 mg (84.9 L/min) was observed for
Flutiform. Conversely, the FPD of Flutiform was consistent
(p > 0.05) when the USP/Ph.Eur. IP was used 51 6 mg (28.3 L/
min) and 57  2 mg (84.9 L/min) but the FPD of the Foster and
Flixotide products both increased with increasing sampling rate.
For all three commercial products, the MMAD observed when
using the A-AIT was lower at 89.4 L/min (Foster 1.2 mm; Flixotide
2.6 mm; Flutiform 3.4 mm) than at 28.3 L/min (Foster 1.4 mm;
Flixotide 2.8 mm; Flutiform 3.7 mm).
6.3. Discussion
These results suggest that aerosols with a ﬁner APSD may
exhibit behavior that is relatively independent of ﬂow rate withinFig. 7. Effect of ﬂow rate & IP upon measured ﬁne particle dose.more complex geometries (Usmani et al., 2003); a feature that may
enable more controlled delivery and drug deposition across patient
groups with different inspiratory proﬁles.
7. Conclusions
In-vitro MDI characterisation is conventionally performed at
28.3 L/min; far lower than reported typical patient inhalation ﬂow
rates of greater than 90 L/min. These investigations of the impact of
sampling ﬂow rate suggest that such practice may result in the
measurement of FPDs that are relatively low, with higher sampling
ﬂow rates producing higher FPDs, comparable to those obtained
with a VHC. A survey of the patient instruction leaﬂets (PILs) of
various marketed products found that patients are instructed to
breathe in ‘slowly and deeply’ or ‘steadily and deeply’ when using
their MDI. However, the ﬁndings of this study challenge this advice,
since they suggest that increased ﬂow rate at the mouthpiece
enables the performance of a solution MDI to match the optimised
atomisation and evaporation achieved when using a VHC.
In addition, these studies suggest that at high ﬂow rates IP
choice (A-AIT or USP/Ph.Eur.) also have an effect on measured FPD
with the results suggesting that aerosols with a ﬁner APSD (Lewis,
2015) may exhibit behaviour that is more independent of ﬂow rate
when measurements are carried out using the more patient
representative A-AIT. This is an advantageous feature of ﬁner
aerosols that may enable more controlled delivery across patients
groups with different inspiratory proﬁles.
The results of the three studies in combination suggest that
there is potential to reﬁne the standard test set-up for MDIs to
produce results that are more clinically relevant. This could have a
positive impact on product development and/or current clinical
practices. There is now a substantial amount of data to suggest it
may be time to re-evaluate the industry standards for in vitro
methods of MDI evaluation, to take into account device resistance,
patient inspiratory ability and proﬁle, formulation components, to
ensure that the full potential of MDI technology is being realised.
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